Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 4,595 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Crossover Clear all
Completed Phase 3 Interventional

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

NCT00006348
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ondansetron, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants

NCT04565678
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Mitapivat tablets, Mitapivat coated granules
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users

NCT03509285
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Alprazolam Placebo, Cenobamate placebo, Alprazolam, Cenobamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 28, 2026, 10:52 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

NCT06916143
View directory record Official record
Conditions
Healthy Participants
Interventions
LY4100511, Rabeprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Phase 3 Interventional

Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)

NCT02622958
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
PH94B, Placebo
Drug · Other
Lead sponsor
Pherin Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Phase 2 Interventional Results available

BIBW 2992 (Afatinib) in Head & Neck Cancer

NCT00514943
View directory record Official record
Conditions
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions
BIBW 2992, Cetuximab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
18
States / cities
Stanford, California • Chicago, Illinois • Harvey, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Phase 2 Interventional

Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B

NCT06205615
View directory record Official record
Conditions
Wound Bleeding
Interventions
BXP154B, Placebo, Punch Biopsy
Drug · Procedure
Lead sponsor
Bio 54, LLC
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

NCT05681715
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Orange, California • San Francisco, California • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Phase 1 Interventional Results available

An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis

NCT02189252
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Epanova, Lovaza
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

NCT05569421
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

NCT01366547
View directory record Official record
Conditions
Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2011 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A

NCT01233258
View directory record Official record
Conditions
Hemophilia A
Interventions
rFVIII (BAY81-8973) on demand, rFVIII (BAY81-8973) prophylaxis low-dose, rFVIII (BAY81-8973) prophylaxis high-dose
Biological
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Dayton, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Phase 1 Interventional

OCR002-SP103 - Oral Immediate Release Study

NCT03846843
View directory record Official record
Conditions
Cirrhosis
Interventions
OCR-002 IR Oral Tablet, OCR-002 Oral Solution, OCR-002 IV Solution
Drug
Lead sponsor
Ocera Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Coronado, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rapid Effects on Antioxidant Status, Immune Alertness, and Regenerative Activity

NCT07142720
View directory record Official record
Conditions
Immune Surveillance, Stem Cell Surveillance
Interventions
A low dose of seaweed extract, A high dose of seaweed extract, Placebo
Dietary Supplement
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 28, 2026, 10:52 PM EDT
Withdrawn Phase 2 Interventional

Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal

NCT06176794
View directory record Official record
Conditions
Heart Failure
Interventions
Immediate release torsemide 20mg tablet, Extended release torsemide 24mg tablet
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Clinical Evaluation of Approved Contact Lenses

NCT02540122
View directory record Official record
Conditions
Vision Disorders
Interventions
Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, Marketed Contact Lens 4
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Phase 1 Interventional

Clinical Trial of Acamprosate for Tinnitus

NCT00596531
View directory record Official record
Conditions
Tinnitus
Interventions
Acamprosate, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Oct 28, 2026, 10:52 PM EDT
Withdrawn Not applicable Interventional

Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops

NCT01306266
View directory record Official record
Conditions
Chronic Post-traumatic Headache
Interventions
Rizatriptan, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 49 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Phase 2 Interventional

Octanol to Treat Essential Tremor

NCT00080366
View directory record Official record
Conditions
Essential Tremor
Interventions
1-Octanol
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2007 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neurophysiological Effects on tPCS and tDCS on Healthy Subjects and on Patients With Chronic Visceral Pain

NCT02497196
View directory record Official record
Conditions
Visceral Pain, Pancreatitis, Pelvic Pain
Interventions
Active tPCS, Active tDCS, Sham tPCS, Sham tDCS
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Compensation With Substitution of Meat Products With White Button Mushrooms.

NCT00198770
View directory record Official record
Conditions
Obesity
Interventions
dietary substitution to assess level of caloric compensation
Dietary Supplement
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 28, 2026, 10:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of ASEA on Energy Expenditure and Fat Oxidation in Humans

NCT01884727
View directory record Official record
Conditions
Obesity
Interventions
Salt Water, ASEA water
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 28, 2026, 10:52 PM EDT
Withdrawn Phase 4 Interventional

Trial of Hydrocortisone for Post-Traumatic Stress Disorder (PTSD)

NCT00706173
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
Hydrocortisone, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 28, 2026, 10:52 PM EDT
Recruiting Phase 2 Interventional

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

NCT06955169
View directory record Official record
Conditions
Intracranial Meningioma
Interventions
[177Lu]Lu-DOTATATE, Standard of Care treatments
Drug · Other
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
17
States / cities
Irvine, California • La Jolla, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 28, 2026, 10:52 PM EDT